Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company focused on developing novel therapeutics for pathologic mineralization and intimal proliferation, recently announced that Doug Treco, Ph.D., CEO and Chairman of the company, will be participating in a fireside chat at the Bank of America Securities 2024 Health Care Conference. The event is scheduled to take place on Wednesday, May 15, 2024, from 6:40-7:10pm ET / 3:40-4:10pm PT.
A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events. A replay of the event will also be available for a limited time for those unable to attend the live chat.
Inozyme Pharma is dedicated to developing innovative treatments for diseases affecting the vasculature, soft tissue, and skeleton. The company is currently working on INZ-701, an enzyme replacement therapy designed to address pathologic mineralization and intimal proliferation, which are known to significantly impact the health outcomes of individuals with severe diseases such as ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
For more information about Inozyme Pharma and its ongoing research and development efforts, please visit their website at https://www.inozyme.com/ or follow the company on social media platforms like LinkedIn, Twitter, and Facebook.
For investor inquiries, please contact Stefan Riley, Senior Director of IR and Corporate Communications at Inozyme Pharma at (857) 330-8871 or via email at stefan.riley@inozyme.com. Media inquiries can be directed to Matt Pera of SmithSolve at (973) 886-9150 or matt.pera@smithsolve.com.